Last reviewed · How we verify
Liposomal doxorubicin hydrochloride
Liposomal doxorubicin hydrochloride, marketed by Cephalon, Inc., is an established oncology treatment with a key composition patent expiring in 2028. Its liposome-encapsulated formulation provides targeted delivery to cancer cells, enhancing efficacy and reducing systemic toxicity compared to conventional doxorubicin. The primary competitive threat comes from Doxil (Janssen Pharmaceuticals) and Caelyx (Pfizer), which also offer liposomal formulations of doxorubicin.
At a glance
| Generic name | Liposomal doxorubicin hydrochloride |
|---|---|
| Also known as | Myocet® |
| Sponsor | Cephalon, Inc. |
| Drug class | Antineoplastic agent |
| Target | DNA and topoisomerase II |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
Pipeline indications
Common side effects
Drug interactions
- Concomitant use with other myelosuppressive agents may increase the risk of hematologic toxicity.
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma (PHASE1)
- A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (PHASE3)
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas (PHASE1)
- A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) (PHASE3)
- A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer (PHASE1)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US7897765B2 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposomal doxorubicin hydrochloride CI brief — competitive landscape report
- Liposomal doxorubicin hydrochloride updates RSS · CI watch RSS
- Cephalon, Inc. portfolio CI